LAVA Medtech Acquisition Corp.
Status: Liquidated
U=S+W/2
W=S@11.5
IPO Proceeds, $M | $115.00M |
---|---|
IPO Date | Oct 27, 2021 |
CEO | Anthony Natale |
Left Lead | RBC Capital Markets |
IPO Cash in Trust | 102.5% |
SPAC Tenor | 18 months |
IPO Sector |
Healthcare
Innovative, development- or early commercial-stage companies focused on clinically-impactful and high growth opportunities within medical devices, diagnostics, and digital health |
IPO Geography | US/Canada |
Target Company | N/A |
Deal Announced | N/A |
Deal Size, $M | TBD |
Deal Sector | TBD |
Deal Geography | TBD |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | Apr 25, 2023 |
Closing Date | May 15, 2023 |
LVAC
LVACU
LVACW
Price | |
---|---|
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on LAVA Medtech Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 10 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Anthony Natale | Chief Executive Officer and Director | |
Richard Emmitt | Chairman and Director | |
Gerry Brunk | President and Director | |
Daniel Hetu | Executive Vice President | |
Vasco Larcina | Chief Financial Officer | |
Peter van der Velden | Director | |
Fritz A. LaPorte | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
RBC Capital Markets | BR | 10,000,000 | units |
10,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 10 filings.